AXL与对表皮生长因子受体（EGFR）抑制剂的获得性耐药 - Suppr

Suppr

超能文献

AXL and acquired resistance to EGFR inhibitors.

作者信息

Postel-Vinay Sophie, Ashworth Alan

出版信息

Nat Genet. 2012 Jul 27;44(8):835-6. doi: 10.1038/ng.2362.

DOI:10.1038/ng.2362

PMID:22836088

Abstract

摘要

相似文献

AXL and acquired resistance to EGFR inhibitors.

Nat Genet. 2012 Jul 27;44(8):835-6. doi: 10.1038/ng.2362.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.

Cell Death Dis. 2019 May 1;10(5):361. doi: 10.1038/s41419-019-1601-6.

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

Cancer Res. 2014 Jan 1;74(1):253-62. doi: 10.1158/0008-5472.CAN-13-1103. Epub 2013 Oct 28.

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.

Thorac Cancer. 2019 Oct;10(10):1928-1935. doi: 10.1111/1759-7714.13166. Epub 2019 Aug 16.

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.

Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.

Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.

Cancer Sci. 2024 Oct;115(10):3333-3345. doi: 10.1111/cas.16292. Epub 2024 Jul 22.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.

Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0.

AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.

Cancer Sci. 2025 Apr;116(4):1034-1047. doi: 10.1111/cas.70006. Epub 2025 Feb 4.

Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.

Int J Cancer. 2019 Sep 15;145(6):1609-1624. doi: 10.1002/ijc.32487. Epub 2019 Jun 25.

引用本文的文献

Gas6-Axl Signaling Induces SRF/MRTF-A Gene Transcription via MICAL2.

Genes (Basel). 2023 Dec 18;14(12):2231. doi: 10.3390/genes14122231.

Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.

Int J Mol Sci. 2021 Feb 20;22(4):2100. doi: 10.3390/ijms22042100.

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment.

Cancers (Basel). 2020 Jun 15;12(6):1587. doi: 10.3390/cancers12061587.

HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.

J Biol Chem. 2018 Oct 5;293(40):15397-15418. doi: 10.1074/jbc.RA118.003063. Epub 2018 Aug 14.

Kinase inhibitors: the road ahead.

Nat Rev Drug Discov. 2018 May;17(5):353-377. doi: 10.1038/nrd.2018.21. Epub 2018 Mar 16.

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.

Mol Cancer. 2018 Feb 19;17(1):60. doi: 10.1186/s12943-018-0816-y.

Dual gene activation and knockout screen reveals directional dependencies in genetic networks.

Nat Biotechnol. 2018 Feb;36(2):170-178. doi: 10.1038/nbt.4062. Epub 2018 Jan 15.

MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer.

Contrast Media Mol Imaging. 2017 May 14;2017:1686525. doi: 10.1155/2017/1686525. eCollection 2017.

A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.

Oncotarget. 2016 Sep 27;7(39):63924-63936. doi: 10.18632/oncotarget.11737.

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.

PLoS One. 2016 Apr 21;11(4):e0154186. doi: 10.1371/journal.pone.0154186. eCollection 2016.

本文引用的文献

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.

Targeting Axl and Mer kinases in cancer.

Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20.

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Clin Cancer Res. 2011 Oct 1;17(19):6298-303. doi: 10.1158/1078-0432.CCR-11-1468. Epub 2011 Aug 19.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Clin Cancer Res. 2011 Mar 15;17(6):1616-22. doi: 10.1158/1078-0432.CCR-10-2692. Epub 2010 Dec 6.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Expert Opin Ther Targets. 2010 Oct;14(10):1073-90. doi: 10.1517/14728222.2010.515980.

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.

Oncogene. 2010 Sep 23;29(38):5254-64. doi: 10.1038/onc.2010.268. Epub 2010 Jul 5.

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.

Comparing antibody and small-molecule therapies for cancer.

Nat Rev Cancer. 2006 Sep;6(9):714-27. doi: 10.1038/nrc1913.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. doi: 10.1073/pnas.0405220101. Epub 2004 Aug 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验